The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Thu., Sep. 29, 2:41 AM

Slide #11. MyoKardia, Inc. Secondary Offering

Company: MyoKardia, Inc. (NASDAQ:MYOK)
Date announced: 9/26/2016
Shares Offered: 3,800,000
Date of Pricing: 9/27/2016
Price Per Share: $15.00
Secondary Offering Details: MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has commenced an underwritten public offering of 3,800,000 shares of its common stock. All shares of common stock will be offered by MyoKardia. In addition, MyoKardia expects to grant the underwriters a 30-day option to purchase up to an additional 570,000 shares of common stock at the public offering price, less the underwriting discount. -updated 9/27- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the pricing of an underwritten public offering of 3,800,000 shares of its common stock at a public offering price of $15.00 per share, before underwriting discounts. In addition, the underwriters have a 30-day option to purchase up to an additional 570,000 shares of common stock on the same terms and conditions.

MyoKardia is a clinical stage biopharmaceutical company that discovers, develops and commercializes targeted therapies for the treatment of cardiovascular diseases. Co.'s lead candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to heritable cardiomyopathy—hypertrophic cardiomyopathy (HCM). Co.'s second program is DCM-1, a drug compound designed to treat heritable dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart. Co. also has two discovery programs, HCM-2, which reduces cardiac muscle contractility to normal levels in HCM patients; and LUS-1, which counteracts muscle disruption.

MYOK SEC Filing Email Alerts Service

Open the MYOK Page at The Online Investor »

Company Name:  MyoKardia Inc
Website:  www.myokardia.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding MYOK:  12
Total Market Value Held by ETFs:  $4.67M
Total Market Capitalization:  $457.00M
% of Market Cap. Held by ETFs:  1.02%
 

Open the MYOK Page at The Online Investor (in a new window) »

September 29, 2016    2:41 AM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
86th percentile
(ranked higher than approx. 86% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.